Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + gemcitabine + paclitaxel + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Hoosier Cancer Research Network
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SGP+P is a combination chemo-immunotherapy regimen consisting of sunitinib, gemcitabine, paclitaxel, and pembrolizumab. It has been primarily investigated for the treatment of advanced or metastatic urothelial carcinoma (bladder cancer). The regimen integrates the multi-targeted tyrosine kinase inhibitor sunitinib, which inhibits vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR) to disrupt tumor angiogenesis, with the cytotoxic chemotherapy agents gemcitabine and paclitaxel. Gemcitabine acts as a nucleoside analog that inhibits DNA synthesis, while paclitaxel stabilizes microtubules to prevent cell division. The addition of pembrolizumab, a monoclonal antibody targeting the programmed death receptor-1 (PD-1), serves to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby reactivating the patient's immune system to recognize and attack malignant cells. This multi-pronged approach aims to overcome resistance and improve outcomes in patients with aggressive urothelial malignancies.
- Other names
- SGP plus pembrolizumabSGP-pembrolizumab
02
Targets
DNA polymerase familyFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RRM1TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)DNACSF1R (Macrophage colony-stimulating factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sunitinib + gemcitabine + paclitaxel + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + gemcitabine + paclitaxel + pembrolizumab.